10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Swedish biotech Lokon Pharma, currently developing LOAd703, a potent double-armed (TMZ-CD40L/4-1BBL) oncolytic adenovirus for solid tumors, has announced a collaboration with Swiss pharma giant, Roche. 3 July 2019
The total spinal muscular atrophy (SMA) market was estimated to be worth $1.5 billion across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, UK and Japan) in 2018. 3 July 2019
Belgium’s Confo Therapeutics has signed a drug discovery deal with Dresden, Germany-based DyNAbind, focused on an undisclosed G-protein coupled receptor (GPCR). 3 July 2019
US biotech Amicus Therapeutics has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics. 2 July 2019
US biotech Incyte and China and USA-based Zai Lab have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. 2 July 2019
Nicox has entered into an exclusive license agreement with China’s Ocumension Therapeutics for the development and commercialization of Nicox’ product candidate, NCX 4251. 2 July 2019
Israel’s leading drugmaker Teva Pharmaceutical has presented data from exploratory endpoints from the Phase IIIb FOCUS trial of Ajovy (fremanezumab), at the annual congress of the European Academy of Neurology (EAN). 2 July 2019
National Health Service patients in the UK will be the first to gain access in Europe to new skin cancer treatment, Libtayo (cemiplimab), through the Cancer Drugs Fund (CDF), it was revealed today, just a day after the drug won conditional regulatory approval from the European Commission. 2 July 2019
The precision medicine hypothesis that the genetics of a patient’s cancer will determine their response to a treatment has been thrown into doubt by new research by the UK’s Institute of Cancer Research (ICR). 1 July 2019
Libtayo (cemiplimab) has been granted conditional approval for the treatment of certain adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one of the most commonly diagnosed skin cancers worldwide. 1 July 2019
Germany’s Boehringer Ingelheim today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of non-alcoholic steatohepatitis (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. 1 July 2019
Novartis has grabbed many of the recent headlines in the field of spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. 1 July 2019
Opthalmology specialist Ocular Therapeutix has launched its lead product in the USA for the treatment of ocular inflammation and pain following ophthalmic surgery. 1 July 2019
Sun Pharmaceutical Industries has entered into a licensing agreement with a subsidiary of China Medical System Holdings (CMS) for the development and commercialization of tildrakizumab in Greater China. 1 July 2019
Despite competition in the anti-CGRP migraine therapy space, Swiss pharma giant Novartis’ Aimovig (erenumab) has become the most-prescribed in the since its launch last year. 1 July 2019
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Privately-held Danish vaccines specialist AJ Vaccines has won approval in Denmark for its adjuvanted IPV vaccine, after positive results from clinical trials involving almost 3,000 infants. 28 June 2019
Danish drugmaker Genmab has won US approval for Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd) to treat people with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). 28 June 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024